HCP Access Only

Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD

Singapore, 14 May 2025 – The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils who are on a stable combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

Digital Health

Doctor, You’re Trending. Now What?

Doctor influencers are rising on TikTok and Instagram, but going viral comes with risks. Here’s how medical professionals can create content that’s engaging, without compromising ethics or professionalism.

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.
Select your currency
SGD Singapore dollar

Don’t have an account? Click here to register

[ultimatemember form_id="29399"]

If have account, Click here to login